WO2003036255A2 - Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property - Google Patents
Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property Download PDFInfo
- Publication number
- WO2003036255A2 WO2003036255A2 PCT/US2002/030849 US0230849W WO03036255A2 WO 2003036255 A2 WO2003036255 A2 WO 2003036255A2 US 0230849 W US0230849 W US 0230849W WO 03036255 A2 WO03036255 A2 WO 03036255A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucose oxidase
- colonies
- formulating
- enzyme according
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
Definitions
- Embodiments of the present invention claim priority from a U.S. Provisional Application entitled "Method For Formulating A Glucose Oxidase Enzyme With A Desired Property Or Properties And A Glucose Oxidase Enzyme With The Desired Property," Serial No. 60/335,585, filed October 23, 2001, the contents of which are incorporated by reference herein.
- the present invention relates, generally, to a method employing directed evolution techniques for formulating a glucose oxidase enzyme possessing a certain desired property or properties, and, in particular embodiments, for formulating a glucose oxidase enzyme having peroxide-resistant characteristics for use, by way of example, in a sensing device.
- biosensors and microelectronics have resulted in the availability of portable diagnostic medical equipment and has improved the quality of life for countless people.
- many diabetics currently utilize diagnostic medical equipment in the comfort of their own homes the vast majority of such devices still require diabetics to draw their own blood and to inject their own insulin. Drawing blood typically requires pricking a finger.
- An example of the type of implantable sensing system described in that application contains a sensing device that is inserted into a vein, an artery, or any other part of a human body where it could sense a desired parameter of the implant environment.
- An enzyme may be placed inside of the sensing device and employed for sensing.
- one or more proteins may be used as the matrix.
- the device is a glucose-sensing device, then a combination of glucose oxidase (GOx) and human serum albumin (HSA) may be utilized to form a sensor matrix protein.
- the sensor matrix protein is disposed adjacent to or near a metal electrode or electrodes that may detect oxygen electrochemically.
- the glucose oxidase works in the glucose sensor by utilizing oxygen to convert glucose to gluconic acid.
- a proposed mechanism of this reaction is illustrated in Figure 1.
- Two proposed mechanisms are illustrated in Figure 1. One mechanism involves the hydride transfer from flavine adenine dinucleotide coenzyme (FAD). The other mechanism involves the formation of the glucosidic link. Glucose reacts as a catalyst to produce the active form of the reduced glucose oxidase (IN).
- glucose oxidase is oxidized (N) as a result.
- the oxidation of glucose oxidase also results in the formation of a hydroperoxy adduct which transforms into hydrogen peroxide.
- oxidized glucose oxidase is inactivated (NI).
- NI oxidized glucose oxidase
- the inactive form will eventually become active (VII) and the cycle is repeated upon the reaction of another glucose molecule.
- the exact mechanism of this process is unknown.
- An obstacle to creating sensors that are long-lived and stable over time has been that glucose oxidase, when immobilized (e.g., for use in a sensor) undergoes oxidative inactivation by the aforementioned peroxide over time.
- glucose oxidase Since the lifetime of glucose sensors primarily depends on the lifetime of glucose oxidase, the effects of the peroxide on the glucose oxidase can severely limit the lifetimes of glucose sensors. It is believed that immobilized glucose oxidase undergoes oxidative inactivation by peroxide over time because the peroxide attacks amino acids involved in binding either substrate or FAD. For example, methionine 561 is an amino acid that is involved in binding FAD to glucose oxidase. Since methionine 561 can be easily oxidized by peroxide, it might be a prime peroxide target. Moreover, glucose oxidase binds glucose and uses oxygen to produce gluconic acid and peroxide.
- Hydroperoxy adducts are some of the intermediates in this process.
- the presence of such adducts along with oxygen and peroxide can result in superoxide radicals which, in effect, may attack both glucose and FAD binding sites.
- Histidines 516 and 559 are prime peroxide targets.
- Both of these amino acids are involved in binding glucose. Oxidation of such amino acids may result in deactivation of the glucose oxidase.
- a glucose oxidase enzyme that is resistant to peroxide.
- Such an enzyme could, for example, be suitable for use in glucose biosensors because the enzyme's peroxide resistant properties might enhance the enzyme's longevity, and in turn, enhance the sensor's stability over time.
- a glucose oxidase enzyme with desired properties, such as peroxide- resistant properties. It is a further advantage of embodiments of the present invention that, while evolution under non-stress circumstances takes years, evolution may be manipulated in embodiments of the invention for specific biological characteristics or enzymatic functions. In embodiments of the invention, this technique, known as directed evolution, may be employed to evolve, for example, glucose oxidase in order to formulate a glucose oxidase that possesses improved resistance to oxidative damage, or, improved resistance to peroxide, or some other desired property.
- directed evolution may be employed to evolve, for example, glucose oxidase in order to formulate a glucose oxidase that possesses improved resistance to oxidative damage, or, improved resistance to peroxide, or some other desired property.
- a method for formulating glucose oxidase with improved peroxide-resistant properties may be used, for example, in glucose biosensors.
- a glucose oxidase exhibiting improved peroxide resistance formulated pursuant to the method provided in the current invention may improve the longevity of a biosensor in which it is employed as compared to a glucose oxidase not formulated pursuant to the method provided herein.
- a method comprises obtaining a glucose oxidase gene or genes and employing the gene or genes to create a library of mutant genes or a library of variants. Each of the library of mutants is inserted into a separate expression vector.
- Each expression vector is then inserted into a host organism where a colony of the host organism can grow, thereby replicating the mutated genes.
- the library of colonies is then screened for desirable properties.
- the screening procedures comprises screening for active glucose oxidase, screening for peroxide resistant properties, and then screening for functionality.
- the glucose oxidase from one or more of these colonies may be mutated into a second generation library of mutants. The process may then proceed again with the second generation mutations. In other embodiments, this same process may be repeated many times on subsequent generations of mutated genes until a gene is formulated with suitable properties.
- Another embodiment of the invention involves, for example, a library of organisms, all of which contain glucose oxidase.
- this library of organisms is grown in separate colonies with a conventional growth medium.
- the environment of each colony is subsequently altered.
- the environment of each colony may be altered by introducing peroxide to it.
- a screening procedure may be employed after the environments of the colonies have been altered. The screening procedure may involve processes of determining which of the colonies contain active glucose oxidase. Those colonies that still contain active glucose oxidase after their environments have been altered may possess desirable peroxide resistant qualities.
- Glucose oxidase from those colonies still containing active glucose oxidase may be tested for functionality, for example, by immobilizing the glucose oxidase in a sensor.
- the environments of the colonies may be altered another time if desired. For example, in one embodiment, altering the environments of the colonies by adding more peroxide may reduce the number of colonies that proceed to the functionality testing.
- Figure 1 shows a flow diagram of a glucose oxidase reaction sequence.
- Figure 2 shows a flowchart diagram of an embodiment of a method for formulating an enzyme with improved peroxide-resistant properties using directed evolution.
- Figure 3 shows a flowchart diagram of a screening procedure used in an embodiment of a method for formulating an enzyme with improved peroxide-resistant properties.
- Figure 4 shows a flowchart diagram of another embodiment of a method for formulating an enzyme with improved peroxide-resistant properties using directed evolution.
- Figure 5 shows a flow diagram of a directed evolution procedure according to one embodiment of the invention utilizing gene shuffling.
- Embodiments of the invention are directed to processes for formulating a glucose oxidase enzyme with a particular desired property, such as, for example, an improved resistance to peroxide.
- Embodiments of the invention employ forced mutations that yield glucose oxidase enzymes that may or may not have an improved characteristic, such as an improved resistance to peroxide. Screening and/or testing procedures may be employed to assist in identifying mutated enzymes that might have desired qualities, such as peroxide resistant qualities.
- An enzyme derived from embodiments of the invention may be suitable for use, for example, in a biosensor. An enzyme derived from these embodiments may improve the performance and stability of a sensor.
- Various biosensor configurations employ active enzymes as part of the sensor structure.
- Embodiments of the invention may be employed to produce active enzymes for various types of sensors.
- a process produces an enzyme for use in a sensor as described in co-pending U.S. Patent Application "Method For Formulating And Immobilizing A Matrix Protein And A Matrix Protein For Use In A Sensor," filed December 27, 2001, (attorney docket number 047711-0288).
- Figure 2 shows a flowchart diagram of a process for utilizing a directed evolution procedure to formulate an enzyme having an improved resistance to peroxide, according to an embodiment of the invention. Initially, the embodiment illustrated in Figure 2 involves selecting or obtaining several glucose oxidase genes.
- the glucose oxidase genes can be taken from, for example, a yeast or a bacteria.
- the glucose oxidase genes are taken from Aspergillus Niger ("A. Niger").
- A. Niger Aspergillus Niger
- the genes could be derived from any member of a group including, but not limited to, A. Niger, Penecillium funiculosum, Saccharomyces cerevisiae, escherichia coli (E. Col ⁇ ), and the like.
- the glucose oxidase genes could also be derived from other similar yeasts or bacteria.
- a library of mutant genes or variants may be created.
- a mutation refers to a random change in a gene or chromosome resulting in a new trait or characteristic that can be inherited.
- the process of creating a library of mutants represents a change in the enzyme. Mutation can be a source of beneficial genetic variation, or it can be neutral or harmful in effect. In these embodiments, the library of mutants may be created without necessarily knowing in advance whether any of the mutants will have the desired characteristics.
- the library of mutants or variants may be created in any of a number of ways. For example, the library of mutants could be created by procedures such as, but not limited to, Error-Prone Polymerase Chain Reaction ("Error-Prone PCR”), gene shuffling, and other like procedures. In one embodiment, Error-Prone PCR may be employed to create the library of mutant genes.
- the library of mutants may be created by a gene shuffling process.
- gene shuffling a library of variants is created by recombining two or more parent genes. The recombined gene sequences may or may not yield functional enzymes. However, the functionality of the enzymes will be tested during the screening procedure. More importantly, the gene-shuffled library of variants will yield a suitable genetic diversity.
- Figure 5 shows a flow diagram of a directed evolution procedure employing a gene-shuffling process for creating a library of mutants.
- the example embodiment in Figure 2 involves inserting each of the mutated genes of the library of mutants into separate expression vectors.
- a gene may not be transferred directly from its original or source organism to a host organism.
- One way, however, to introduce a mutated gene into a host organism is to first introduce a gene into a vector.
- a vector is able to carry the gene into a host organism.
- each of the mutated genes may be inserted into an expression vector.
- each of the library of mutated genes which have been inserted into separate expression vectors are inserted into separate host organisms.
- the host organisms may be, for example, rapidly reproducing microorganisms which might be able to duplicate the recombined or mutated gene in large quantities.
- suitable host organisms include E. Coli, A. Niger, and the like. Those skilled in the art will understand that other suitable host organisms are also available.
- E. Coli may be employed as the host bacteria.
- each of the host organisms or bacteria may be placed into separate cells of a plate or tray. Within these separate cells, colonies of each of the host organisms or bacteria may be grown using any conventional growth medium.
- any other suitable holder or receptacle in which the host organisms or bacteria could grow would also work.
- each of the host organisms or bacteria could be placed in their own separate plates or trays.
- a screening procedure is employed in the example embodiment.
- the screening procedure is illustrated in Figure 3. Initially, the screening procedure involves testing for glucose oxidase. A given colony may not necessarily yield active glucose oxidase following the gene mutation, the injection into the bacteria, and the growth process. Accordingly, the example embodiment includes determining whether the mutated genes that have been growing in the host organisms or bacteria yield active glucose oxidase.
- the test to determine whether a given colony contains active glucose oxidase may be conducted in any of a variety of ways.
- the test for whether active glucose oxidase is present in a given colony comprises an assay which tests the production of peroxide. Peroxide is generated upon glucose oxidase reaction with glucose. In one embodiment, leuco-crystal-violet, a substrate that changes color in the presence of active peroxide, is employed. However, in other embodiments, other substances may also be used such as, but not limited to, aminoantipyrine, and the like. In other embodiments, other methods can be used to test for the presence of active glucose oxidase.
- the presence or absence of active glucose oxidase may be ascertainable by checking for fluorescence. The more fluorescent a given colony is, the more likely it is that it contains active glucose oxidase. Those skilled in the art will appreciate that further methods to test for the presence of glucose oxidase can be employed in other embodiments without deviating from the scope or spirit of the invention. As illustrated in Figure 3, if it is determined that a given colony does not contain active glucose oxidase, then the sample in that colony will not be acceptable because a goal of the process is to formulate a peroxide resistant glucose oxidase. Accordingly, in the example embodiment, for colonies in which active glucose oxidase is present, then the process proceeds to the next step in the screening procedure.
- the screening procedure in the example embodiment next involves determining whether the active glucose oxidase in the colonies that passed the first test in the screening procedure has peroxide-resistant properties.
- this portion of the screening procedure involves first incubating each remaining colony in peroxide. This may be done, for example, by placing a suitable amount of peroxide into the cells of the tray in which the colonies were grown. Other embodiments may introduce suitable amounts of peroxide to the various colonies other ways. For example, the peroxide may be introduced to the various colonies in separate trays or other receptacles.
- each colony may be tested for active glucose oxidase in similar ways as described above. Accordingly, after each of the remaining colonies has been incubated in peroxide, they may again be tested for glucose oxidase by, for example, using leuco-crystal-violet, a substrate which changes color in the presence of glucose oxidase.
- Other embodiments could use a different means for testing for active glucose oxidase without straying from the scope or spirit of the invention.
- the colonies could be incubated in peroxide and then tested for glucose oxidase activity one colony at a time or more than one colony at a time.
- all colonies first be incubated in peroxide before any of the them can be tested for glucose oxidase.
- any of the remaining colonies tested negative for active glucose oxidase after the peroxide incubation process then they may be deemed not acceptable.
- the colonies that still have active glucose oxidase, after being incubated in peroxide may exhibit a desirable peroxide-resistive characteristic.
- the screening procedure proceeds to the next step of testing functionality.
- the screening procedure next involves determining whether a given glucose oxidase enzyme possesses the desired functionality.
- the procedure may involve testing whether a given glucose oxidase enzyme will work in a sensing device.
- this part of the screening procedure generally requires that the glucose oxidase be extracted from each of the remaining colonies.
- glucose oxidase may be extracted from the colonies using a purification column.
- the process of assessing a given glucose oxidase enzyme's functionality may proceed as follows. First, cell lysis, or the removal of the protein from the source, may be achieved by a gentle grinding in a homogenizer. It can also be done by gentle disruption via sonication. Other embodiments might employ other means for removing the protein from the source. Next, the cell components may be subject to fractionation using centrifugation techniques and then differential solubility. The protein may subsequently be purified using standard chromatography methods. Next, the extracted protein may be characterized. This may be done by measuring the activity and concentration of the extract. Once the enzyme has been sufficiently isolated and sufficiently concentrated, then it may be immobilized and placed into a sensor.
- the sensor may then be introduced into an accelerated test environment to determine whether the particular enzyme is indeed functional or is suitable for use in a sensing device. If the results of the test with the enzyme in the sensor are satisfactory, then the testing can stop. This test may be repeated with every colony that exhibited peroxide resistant glucose oxidase after the incubation period. In other embodiments, this test could be done on a subset of those colonies depending on other factors or characteristics. If a satisfactory glucose oxidase enzyme has not been identified after the screening procedure, then, in the embodiment illustrated in Figure 2, the process may continue by creating another generation of mutated genes. In the example embodiment in Figure 2, the entire cycle may be repeated as many times as desired.
- FIG. 4 Another embodiment of the process of formulating an enzyme with peroxide-resistive properties is illustrated at Figure 4.
- the example embodiment illustrated at Figure 4 employs a forced mutation process.
- mutations may be created by exposing organisms to harsh environments.
- the embodiment in Figure 4 first involves obtaining an organism, such as A. Niger, penecillium, E. Coli, or any other suitable organism. Since this embodiment will ultimately create a library of mutants as discussed above, the organism may be placed in multiple cells of a plate or tray. Other embodiments could employ other kinds of holders or receptacles in which to grow the organisms so long as the organisms are placed in separate colonies. Another embodiment of the invention may use only a single cell or colony.
- this embodiment involves introducing a growth medium to each cell holding some of the organism.
- the growth medium may be any conventional growth medium such that the organisms may be sustained.
- the embodiment in Figure 4 next involves altering the environments of each of the separated organisms.
- the organisms' environments may be altered by adding a suitable amount of peroxide to each colony.
- the introduction of peroxide to the organisms' environments is done very gradually. In other embodiments, the introduction of peroxide to the organism's environment may be more abrupt.
- the embodiment in Figure 4 next involves a screening procedure.
- the screening procedure may be employed to determine which of the colonies are still active.
- the test discussed above may be employed for determining whether glucose oxidase in each of the colonies remains active.
- Other embodiments may employ other tests for determining whether a given colony contains active glucose oxidase.
- an assessment may be made as to whether the number of colonies with active glucose oxidase is such that the process may proceed to testing the glucose oxidase in sensing devices. Whether the number of remaining colonies is workable may depend on many factors and will vary for different embodiments of the invention.
- the environment may be made harsher by gradually adding more peroxide. In this embodiment, by repeating this cycle as many times as necessary, the environment may be continually and gradually made harsher until only a workable number of viable or active colonies remain. In the example embodiment in Figure 4, once the process yields a workable number of remaining colonies with active glucose oxidase, then the process may proceed to testing the glucose oxidase in sensing devices to assess functionality. The remaining colonies, which may possess the desirable peroxide resistant properties, may be tested for functionality as discussed above.
- this testing may be done by extracting glucose oxidase from the enzymes, incorporating the glucose oxidase in a sensor, and then effecting an accelerated test on the sensor to ascertain the functionality of the enzyme.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003538705A JP2006501802A (en) | 2001-10-23 | 2002-09-27 | Method for preparing glucose oxidase enzyme having one or more desired properties and glucose oxidase enzyme having desired properties |
| EP02773635A EP1444333A4 (en) | 2001-10-23 | 2002-09-27 | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property |
| CA2463905A CA2463905C (en) | 2001-10-23 | 2002-09-27 | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property |
| AU2002337743A AU2002337743A1 (en) | 2001-10-23 | 2002-09-27 | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33558501P | 2001-10-23 | 2001-10-23 | |
| US60/335,585 | 2001-10-23 | ||
| US10/035,918 | 2001-12-28 | ||
| US10/035,918 US20030077702A1 (en) | 2001-10-23 | 2001-12-28 | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003036255A2 true WO2003036255A2 (en) | 2003-05-01 |
| WO2003036255A3 WO2003036255A3 (en) | 2003-11-27 |
Family
ID=26712614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2002/030849 Ceased WO2003036255A2 (en) | 2001-10-23 | 2002-09-27 | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030077702A1 (en) |
| EP (1) | EP1444333A4 (en) |
| JP (1) | JP2006501802A (en) |
| AU (1) | AU2002337743A1 (en) |
| CA (1) | CA2463905C (en) |
| WO (1) | WO2003036255A2 (en) |
Cited By (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008536097A (en) * | 2005-02-17 | 2008-09-04 | メドトロニック ミニメド インコーポレイテッド | Polypeptide formulations and methods for making, using, and analyzing them |
| WO2011041715A2 (en) | 2009-10-01 | 2011-04-07 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having interference rejection membranes and methods for making and using them |
| WO2011063259A2 (en) | 2009-11-20 | 2011-05-26 | Medtronic Minimed, Inc. | Multi-conductor lead configurations useful with medical device systems and methods for making and using them |
| WO2011084651A1 (en) | 2009-12-21 | 2011-07-14 | Medtronic Minimed, Inc. | Analyte sensors comprising blended membrane compositions and methods for making and using them |
| WO2011091061A1 (en) | 2010-01-19 | 2011-07-28 | Medtronic Minimed, Inc. | Insertion device for a combined sensor and infusion sets |
| WO2011115949A1 (en) | 2010-03-16 | 2011-09-22 | Medtronic Minimed, Inc. | Glucose sensor |
| WO2011163303A2 (en) | 2010-06-23 | 2011-12-29 | Medtronic Minimed, Inc. | Sensor systems having multiple probes and electrode arrays |
| EP2415863A1 (en) | 2010-08-03 | 2012-02-08 | B.R.A.I.N. | Mutant glucose oxidase |
| WO2012154548A1 (en) | 2011-05-06 | 2012-11-15 | Medtronic Minimed, Inc. | Method and apparatus for continuous analyte monitoring |
| WO2013177573A2 (en) | 2012-05-25 | 2013-11-28 | Medtronic Minimed, Inc. | Foldover sensors and methods for making and using them |
| WO2014008297A1 (en) | 2012-07-03 | 2014-01-09 | Medtronic Minimed, Inc. | Analyte sensors and production thereof |
| WO2014089276A1 (en) | 2012-12-06 | 2014-06-12 | Medtronic Minimed, Inc. | Microarray electrodes useful with analyte sensors and methods for making and using them |
| WO2014116293A1 (en) | 2013-01-22 | 2014-07-31 | Medtronic Minimed, Inc. | Muting glucose sensor oxygen response and reducing electrode edge growth with pulsed current plating |
| CN104263744A (en) * | 2014-09-11 | 2015-01-07 | 北京化工大学 | Artificially modified glucose oxidase gene and expression application thereof |
| WO2015069692A2 (en) | 2013-11-07 | 2015-05-14 | Medtronic Minimed, Inc. | Enzyme matrices for use with ethylene oxide sterilization |
| WO2017189764A1 (en) | 2016-04-28 | 2017-11-02 | Medtronic Minimed, Inc. | In-situ chemistry stack for continuous glucose sensors |
| WO2017195035A1 (en) | 2016-05-10 | 2017-11-16 | Interface Biologics, Inc. | Implantable glucose sensors having a biostable surface |
| WO2017214173A1 (en) | 2016-06-06 | 2017-12-14 | Medtronic Minimed, Inc. | Polycarbonate urea/urethane polymers for use with analyte sensors |
| US9968742B2 (en) | 2007-08-29 | 2018-05-15 | Medtronic Minimed, Inc. | Combined sensor and infusion set using separated sites |
| WO2018170363A1 (en) | 2017-03-17 | 2018-09-20 | Medtronic Minimed, Inc. | Metal pillar device structures and methods for making and using them in electrochemical and/or electrocatalytic applications |
| WO2019005687A1 (en) | 2017-06-30 | 2019-01-03 | Medtronic Minimed, Inc. | Sensor initialization methods for faster body sensor response |
| WO2019147578A1 (en) | 2018-01-23 | 2019-08-01 | Medtronic Minimed, Inc. | Implantable polymer surfaces exhibiting reduced in vivo inflammatory responses |
| WO2019157043A1 (en) | 2018-02-08 | 2019-08-15 | Medtronic Minimed, Inc. | Glucose sensor electrode design |
| WO2019156934A1 (en) | 2018-02-07 | 2019-08-15 | Medtronic Minimed, Inc. | Multilayer electrochemical analyte sensors and methods for making and using them |
| WO2019157106A2 (en) | 2018-02-08 | 2019-08-15 | Medtronic Minimed, Inc. | Methods for controlling physical vapor deposition metal film adhesion to substrates and surfaces |
| WO2019222499A1 (en) | 2018-05-16 | 2019-11-21 | Medtronic Minimed, Inc. | Thermally stable glucose limiting membrane for glucose sensors |
| WO2021021867A1 (en) | 2019-08-01 | 2021-02-04 | Medtronic Minimed, Inc. | Micro-pillar working electrodes design to reduce backflow of hydrogen peroxide in glucose sensor |
| WO2021021538A1 (en) | 2019-07-26 | 2021-02-04 | Medtronic Minimed, Inc. | Methods to improve oxygen delivery to implantable sensors |
| WO2022026542A1 (en) | 2020-07-31 | 2022-02-03 | Medtronic Minimed, Inc. | Sensor identification and integrity check design |
| WO2022093574A1 (en) | 2020-10-29 | 2022-05-05 | Medtronic Minimed, Inc. | Glucose biosensors comprising direct electron transfer enzymes and methods of making and using them |
| WO2022164981A1 (en) | 2021-01-29 | 2022-08-04 | Medtronic Minimed, Inc. | Interference rejection membranes useful with analyte sensors |
| EP4071251A1 (en) | 2021-04-09 | 2022-10-12 | Medtronic MiniMed, Inc. | Hexamethyldisiloxane membranes for analyte sensors |
| EP4134665A1 (en) | 2021-08-13 | 2023-02-15 | Medtronic MiniMed, Inc. | Dry electrochemical impedance spectroscopy metrology for conductive chemical layers |
| EP4162874A1 (en) | 2021-10-08 | 2023-04-12 | Medtronic MiniMed, Inc. | Immunosuppressant releasing coatings |
| EP4174188A1 (en) | 2021-10-14 | 2023-05-03 | Medtronic Minimed, Inc. | Sensors for 3-hydroxybutyrate detection |
| EP4190908A1 (en) | 2021-12-02 | 2023-06-07 | Medtronic Minimed, Inc. | Ketone limiting membrane and dual layer membrane approach for ketone sensing |
| EP4310193A1 (en) | 2022-07-20 | 2024-01-24 | Medtronic Minimed, Inc. | Acrylate hydrogel membrane for dual function of diffusion limiting membrane as well as attenuation to the foreign body response |
| EP4360550A1 (en) | 2022-10-28 | 2024-05-01 | Medtronic Minimed, Inc. | Enzyme mediator functionalized polymers for use with analyte sensors |
| EP4382611A1 (en) | 2022-08-31 | 2024-06-12 | Medtronic MiniMed, Inc. | Sensors for 3-hydroxybutyrate detection |
| EP4442199A1 (en) | 2023-04-05 | 2024-10-09 | Medtronic Minimed, Inc. | Analyte transporting membranes for use with analyte sensors |
| EP4631428A1 (en) | 2024-03-07 | 2025-10-15 | Medtronic MiniMed, Inc. | Sensor membranes for dexamethosone rejection |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
| US8165651B2 (en) * | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
| US7699964B2 (en) | 2004-02-09 | 2010-04-20 | Abbott Diabetes Care Inc. | Membrane suitable for use in an analyte sensor, analyte sensor, and associated method |
| BRPI0514542A (en) * | 2004-08-24 | 2008-06-17 | Bayer Healthcare Llc | method for determining the concentration of substances analyzed in samples by direct enzyme mediation |
| CA2590944C (en) | 2004-12-13 | 2016-02-02 | Bayer Healthcare Llc | Size self-limiting compositions and test devices for measuring analytes in biological fluids |
| US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
| ES2556605T3 (en) * | 2011-08-25 | 2016-01-19 | F. Hoffmann-La Roche Ag | Glucose oxidase |
| JP6571089B2 (en) | 2013-12-31 | 2019-09-04 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | Built-in power supply type analyte sensor and device using the same |
| CN104312989A (en) * | 2014-10-28 | 2015-01-28 | 江南大学 | Glucose oxidase with improved oxidative resistance |
| CN107189991B (en) * | 2017-05-08 | 2020-05-22 | 中国农业科学院饲料研究所 | A kind of glucose oxidase mutant and its encoding gene and application |
| CN107012130B (en) * | 2017-06-02 | 2020-05-22 | 中国农业科学院饲料研究所 | Glucose oxidase mutant and coding gene and application thereof |
| CN110577939B (en) * | 2018-06-07 | 2021-01-26 | 青岛红樱桃生物技术有限公司 | Glucose oxidase mutant with improved heat resistance as well as coding gene and application thereof |
| CN113403290B (en) * | 2021-05-26 | 2023-02-17 | 广东溢多利生物科技股份有限公司 | Glucose oxidase mutant with improved thermal stability as well as coding gene and application thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5886083A (en) * | 1981-11-12 | 1983-05-23 | Wako Pure Chem Ind Ltd | Stabilizing agent for glycerol-3-phosphoric acid oxidase |
| DE4301904A1 (en) * | 1992-08-07 | 1994-02-10 | Boehringer Mannheim Gmbh | Hypoglycosylated recombinant glucose oxidase |
| EP0705348B1 (en) * | 1993-06-21 | 2001-08-08 | Roche Diagnostics Corporation | Diagnostic reagent stabilizer |
| DE4430023A1 (en) * | 1994-08-24 | 1996-02-29 | Boehringer Mannheim Gmbh | Electrochemical sensor |
| JP3399685B2 (en) * | 1995-03-07 | 2003-04-21 | 東洋紡績株式会社 | Modified enzyme having cholesterol oxidase activity |
| ATE223489T1 (en) * | 1995-06-07 | 2002-09-15 | Danisco | RECOMBINANT HEXOSE OXIDASE, METHOD FOR THE PRODUCTION AND USE THEREOF |
| US6689265B2 (en) * | 1995-10-11 | 2004-02-10 | Therasense, Inc. | Electrochemical analyte sensors using thermostable soybean peroxidase |
| JP2943700B2 (en) * | 1996-07-10 | 1999-08-30 | 日本電気株式会社 | Biosensor |
| EP0969282B1 (en) * | 1998-07-02 | 2011-09-21 | NEC Corporation | An enzyme electrode and a biosensor and a measuring apparatus therewith |
-
2001
- 2001-12-28 US US10/035,918 patent/US20030077702A1/en not_active Abandoned
-
2002
- 2002-09-27 JP JP2003538705A patent/JP2006501802A/en active Pending
- 2002-09-27 WO PCT/US2002/030849 patent/WO2003036255A2/en not_active Ceased
- 2002-09-27 CA CA2463905A patent/CA2463905C/en not_active Expired - Fee Related
- 2002-09-27 EP EP02773635A patent/EP1444333A4/en not_active Withdrawn
- 2002-09-27 AU AU2002337743A patent/AU2002337743A1/en not_active Abandoned
Cited By (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008536097A (en) * | 2005-02-17 | 2008-09-04 | メドトロニック ミニメド インコーポレイテッド | Polypeptide formulations and methods for making, using, and analyzing them |
| US9968742B2 (en) | 2007-08-29 | 2018-05-15 | Medtronic Minimed, Inc. | Combined sensor and infusion set using separated sites |
| WO2011041715A2 (en) | 2009-10-01 | 2011-04-07 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having interference rejection membranes and methods for making and using them |
| WO2011063259A2 (en) | 2009-11-20 | 2011-05-26 | Medtronic Minimed, Inc. | Multi-conductor lead configurations useful with medical device systems and methods for making and using them |
| WO2011084651A1 (en) | 2009-12-21 | 2011-07-14 | Medtronic Minimed, Inc. | Analyte sensors comprising blended membrane compositions and methods for making and using them |
| WO2011091061A1 (en) | 2010-01-19 | 2011-07-28 | Medtronic Minimed, Inc. | Insertion device for a combined sensor and infusion sets |
| US10448872B2 (en) | 2010-03-16 | 2019-10-22 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having improved electrode configurations and methods for making and using them |
| WO2011115949A1 (en) | 2010-03-16 | 2011-09-22 | Medtronic Minimed, Inc. | Glucose sensor |
| WO2011163303A2 (en) | 2010-06-23 | 2011-12-29 | Medtronic Minimed, Inc. | Sensor systems having multiple probes and electrode arrays |
| EP2415863A1 (en) | 2010-08-03 | 2012-02-08 | B.R.A.I.N. | Mutant glucose oxidase |
| WO2012017008A1 (en) | 2010-08-03 | 2012-02-09 | B.R.A.I.N. Biotechnology Research And Information Network Ag | A novel glucose oxidase |
| WO2012154548A1 (en) | 2011-05-06 | 2012-11-15 | Medtronic Minimed, Inc. | Method and apparatus for continuous analyte monitoring |
| WO2013177573A2 (en) | 2012-05-25 | 2013-11-28 | Medtronic Minimed, Inc. | Foldover sensors and methods for making and using them |
| US11020028B2 (en) | 2012-05-25 | 2021-06-01 | Medtronic Minimed, Inc. | Foldover sensors and methods for making and using them |
| WO2014008297A1 (en) | 2012-07-03 | 2014-01-09 | Medtronic Minimed, Inc. | Analyte sensors and production thereof |
| US10772540B2 (en) | 2012-12-06 | 2020-09-15 | Medtronic Minimed, Inc. | Microarray electrodes useful with analyte sensors and methods for making and using them |
| WO2014089276A1 (en) | 2012-12-06 | 2014-06-12 | Medtronic Minimed, Inc. | Microarray electrodes useful with analyte sensors and methods for making and using them |
| US10194840B2 (en) | 2012-12-06 | 2019-02-05 | Medtronic Minimed, Inc. | Microarray electrodes useful with analyte sensors and methods for making and using them |
| WO2014116293A1 (en) | 2013-01-22 | 2014-07-31 | Medtronic Minimed, Inc. | Muting glucose sensor oxygen response and reducing electrode edge growth with pulsed current plating |
| US10426383B2 (en) | 2013-01-22 | 2019-10-01 | Medtronic Minimed, Inc. | Muting glucose sensor oxygen response and reducing electrode edge growth with pulsed current plating |
| US11266332B2 (en) | 2013-01-22 | 2022-03-08 | Medtronic Minimed, Inc. | Muting glucose sensor oxygen response and reducing electrode edge growth with pulsed current plating |
| WO2015069692A2 (en) | 2013-11-07 | 2015-05-14 | Medtronic Minimed, Inc. | Enzyme matrices for use with ethylene oxide sterilization |
| CN104263744A (en) * | 2014-09-11 | 2015-01-07 | 北京化工大学 | Artificially modified glucose oxidase gene and expression application thereof |
| WO2017189764A1 (en) | 2016-04-28 | 2017-11-02 | Medtronic Minimed, Inc. | In-situ chemistry stack for continuous glucose sensors |
| WO2017195035A1 (en) | 2016-05-10 | 2017-11-16 | Interface Biologics, Inc. | Implantable glucose sensors having a biostable surface |
| WO2017214173A1 (en) | 2016-06-06 | 2017-12-14 | Medtronic Minimed, Inc. | Polycarbonate urea/urethane polymers for use with analyte sensors |
| WO2018170363A1 (en) | 2017-03-17 | 2018-09-20 | Medtronic Minimed, Inc. | Metal pillar device structures and methods for making and using them in electrochemical and/or electrocatalytic applications |
| WO2019005687A1 (en) | 2017-06-30 | 2019-01-03 | Medtronic Minimed, Inc. | Sensor initialization methods for faster body sensor response |
| WO2019147578A1 (en) | 2018-01-23 | 2019-08-01 | Medtronic Minimed, Inc. | Implantable polymer surfaces exhibiting reduced in vivo inflammatory responses |
| WO2019156934A1 (en) | 2018-02-07 | 2019-08-15 | Medtronic Minimed, Inc. | Multilayer electrochemical analyte sensors and methods for making and using them |
| WO2019157043A1 (en) | 2018-02-08 | 2019-08-15 | Medtronic Minimed, Inc. | Glucose sensor electrode design |
| WO2019157106A2 (en) | 2018-02-08 | 2019-08-15 | Medtronic Minimed, Inc. | Methods for controlling physical vapor deposition metal film adhesion to substrates and surfaces |
| WO2019222499A1 (en) | 2018-05-16 | 2019-11-21 | Medtronic Minimed, Inc. | Thermally stable glucose limiting membrane for glucose sensors |
| WO2021021538A1 (en) | 2019-07-26 | 2021-02-04 | Medtronic Minimed, Inc. | Methods to improve oxygen delivery to implantable sensors |
| WO2021021867A1 (en) | 2019-08-01 | 2021-02-04 | Medtronic Minimed, Inc. | Micro-pillar working electrodes design to reduce backflow of hydrogen peroxide in glucose sensor |
| WO2022026542A1 (en) | 2020-07-31 | 2022-02-03 | Medtronic Minimed, Inc. | Sensor identification and integrity check design |
| WO2022093574A1 (en) | 2020-10-29 | 2022-05-05 | Medtronic Minimed, Inc. | Glucose biosensors comprising direct electron transfer enzymes and methods of making and using them |
| WO2022164981A1 (en) | 2021-01-29 | 2022-08-04 | Medtronic Minimed, Inc. | Interference rejection membranes useful with analyte sensors |
| EP4071251A1 (en) | 2021-04-09 | 2022-10-12 | Medtronic MiniMed, Inc. | Hexamethyldisiloxane membranes for analyte sensors |
| EP4134665A1 (en) | 2021-08-13 | 2023-02-15 | Medtronic MiniMed, Inc. | Dry electrochemical impedance spectroscopy metrology for conductive chemical layers |
| EP4162874A1 (en) | 2021-10-08 | 2023-04-12 | Medtronic MiniMed, Inc. | Immunosuppressant releasing coatings |
| EP4174188A1 (en) | 2021-10-14 | 2023-05-03 | Medtronic Minimed, Inc. | Sensors for 3-hydroxybutyrate detection |
| EP4190908A1 (en) | 2021-12-02 | 2023-06-07 | Medtronic Minimed, Inc. | Ketone limiting membrane and dual layer membrane approach for ketone sensing |
| EP4310193A1 (en) | 2022-07-20 | 2024-01-24 | Medtronic Minimed, Inc. | Acrylate hydrogel membrane for dual function of diffusion limiting membrane as well as attenuation to the foreign body response |
| EP4382611A1 (en) | 2022-08-31 | 2024-06-12 | Medtronic MiniMed, Inc. | Sensors for 3-hydroxybutyrate detection |
| EP4360550A1 (en) | 2022-10-28 | 2024-05-01 | Medtronic Minimed, Inc. | Enzyme mediator functionalized polymers for use with analyte sensors |
| EP4442199A1 (en) | 2023-04-05 | 2024-10-09 | Medtronic Minimed, Inc. | Analyte transporting membranes for use with analyte sensors |
| EP4631428A1 (en) | 2024-03-07 | 2025-10-15 | Medtronic MiniMed, Inc. | Sensor membranes for dexamethosone rejection |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1444333A2 (en) | 2004-08-11 |
| WO2003036255A3 (en) | 2003-11-27 |
| AU2002337743A1 (en) | 2003-05-06 |
| CA2463905C (en) | 2011-10-18 |
| US20030077702A1 (en) | 2003-04-24 |
| EP1444333A4 (en) | 2004-12-22 |
| JP2006501802A (en) | 2006-01-19 |
| CA2463905A1 (en) | 2003-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2463905C (en) | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property | |
| Tee et al. | Metal nanostructures for non-enzymatic glucose sensing | |
| Updike et al. | The enzyme electrode | |
| JP4648993B2 (en) | Flavin-binding glucose dehydrogenase | |
| Medina et al. | Involvement of glutamic acid 301 in the catalytic mechanism of ferredoxin-NADP+ reductase from Anabaena PCC 7119 | |
| Kahn et al. | Spectroscopic characterization of intermediates in the urate oxidase reaction | |
| JP5969392B2 (en) | Flavin-binding glucose dehydrogenase, method for producing flavin-binding glucose dehydrogenase, and yeast transformant used therefor | |
| JP2003185619A (en) | REAGENT AND METHOD FOR DETECTING ANALYTE AND APPARATUS INCLUDING REAGENT FOR DETECTION OF ANALYTE | |
| EP2647703A1 (en) | E. coli transformant, production method for flavin-bound glucose dehydrogenase using same, and mutant flavin-bound glucose dehydrogenase | |
| JP2017148058A (en) | Biosensor for glucose measurement | |
| JP6526572B2 (en) | Flavin-binding glucose dehydrogenase with improved thermal stability | |
| Malik et al. | An improved enzyme nanoparticles based amperometric pyruvate biosensor for detection of pyruvate in serum | |
| JP7509824B2 (en) | Modified flavin-binding glucose dehydrogenase | |
| JP2010035448A (en) | Modified flavin adenine-dependent glucose dehydrogenase with improved substrate specificity | |
| US20040137547A1 (en) | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property | |
| JP7032906B2 (en) | Composition for glucose redox reaction and glucose measurement using flavin compound | |
| JP6101011B2 (en) | Method for improving the stability of a composition comprising a flavin-binding glucose dehydrogenase | |
| JP6635913B2 (en) | Flavin-binding glucose dehydrogenase with improved specific activity | |
| JP6934720B2 (en) | Flavin-bound glucose dehydrogenase with improved substrate specificity | |
| JP6652757B2 (en) | Mutant protein having flavin adenine dinucleotide-dependent glucose dehydrogenase activity | |
| JP7165493B2 (en) | Glucose dehydrogenase with excellent storage stability and continuous blood glucose measurement | |
| JP2011525361A (en) | Novel variant of PQQ-dependent glucose dehydrogenase with improved substrate specificity | |
| CN106479999A (en) | A kind of L dglutamic oxidase CBD merges enzyme and its expressing gene and application | |
| EP2305803A1 (en) | Thermostable 1,5-anhydroglucitol dehydrogenase, and method for measurement of 1,5-anhydroglucitol by using the same | |
| JP2007513636A (en) | Electrochemical assay for identification of microorganisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2463905 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003538705 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002773635 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002773635 Country of ref document: EP |